following a full submission assessed under orphan medicine process:
mosunetuzumab (Lunsumio®) is not recommended for use within NHSScotland.
Indication under review: as monotherapy for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least two prior systemic therapies.
In a single arm, open label, phase II study, treatment with mosunetuzumab was associated with a complete response rate of 60% in a cohort of patients with relapsed or refractory FL who had received at least two prior therapies.
The submitting company’s justification of the treatment cost in relation to its health benefits was not sufficient and in addition the company did not present a sufficiently robust clinical and economic analysis to gain acceptance by SMC.
This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting.
Download detailed advice803KB (PDF)
Medicine details
- Medicine name:
- mosunetuzumab (Lunsumio)
- SMC ID:
- SMC2542
- Indication:
As monotherapy for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) who have received at least two prior systemic therapies.
- Pharmaceutical company
- Roche
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Status
- Not recommended
- Date advice published
- 11 September 2023